Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy
This study has been completed.
Information provided by:
First received: September 12, 2005
Last updated: December 13, 2011
Last verified: December 2011
The investigators hypothesize that persons with the particular cluster of symptoms that are due to supraesophageal reflux (SER) will have complete resolution of those symptoms with adequate acid suppression when a PPI is administered for 6 months.
Drug: Sugar Pill
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
||Which Supraesophageal Reflux Symptoms Reliably Respond to PPI Therapy: A Large Simple Trial
Primary Outcome Measures:
- To determine which symptom(s) are predictive of SER based on a complete response to PPI therapy [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- To determine which symptoms demonstrate partial response with PPI therapy [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
- To determine which features of a patient's history are predictive of a positive response to PPI therapy [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
- To determine which features of a patient's history are predictive of a lack of response to PPI therapy [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
- To develop a scoring system for the Supraesophageal Reflux Questionnaire (SRQ) that would predict a diagnosis of SER [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2006 (Final data collection date for primary outcome measure)
Placebo Comparator: Sugar pill
Drug: Sugar Pill
40 mg BID
Active Comparator: Active Comparator
40 mg bid dosing
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Primary complaint includes one of the following symptoms: chronic cough (dry, hacking, or nocturnal), hoarseness, sore throat, globus sensation, or throat clearing. These symptoms will be identified by a yes response to SRQ (Appendix 7) items 2, 3, 4, 5, 6, and 8. Furthermore, symptom(s) must be chronic (present for at least 1 month), and recurrent (at least twice per week). These criteria correspond to SRQ columns on page 3-5. The first column asks: When in your life did you first notice this symptom? A response with either number 2, 3, 4, or 5 meets criteria for chronic. The second column asks: How frequently have you noticed the symptom? A response with either number 3, 4, or 5 meets criteria for recurrent.
- History of head and neck cancer/radiation/surgery (SRQ items 15, 16, 17)
- History of esophagus/stomach surgery (SRQ item 22)
- Peptic or duodenal ulcer disease; stomach or gastric ulcer disease; history of esophageal stricture, or Barrett's esophagus, or esophagitis, or tumor of the esophagus or stomach (SRQ item 23 and review of electronic surgical records of Mayo Clinic patients)
- Presence of alarm symptoms (hemoptysis, unexplained loss of 10 or more pounds in the past 3 months), obtained from Appendix 5 for Community Subjects, medical record for clinic subjects. History of dysphagia, defined as a yes answer to SRQ item 7.
- PPI use within 4 weeks, obtained from Appendix 5 for Community Subjects, medical record for clinic subjects
- Use of warfarin or digoxin, obtained from Appendix 5 for Community Subjects, medical record for clinic subjects
- Pregnancy at the time of enrollment, based on urine pregnancy test
- Inability to understand or read English at a 6th grade level
- Residence outside of the United States of America (USA)
- Age younger than 18 years old
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00170001
|Rochester, Minnesota, United States, 55905 |
||Yvonne Romero, M.D.
No publications provided
||Dr. Yvonne Romero, Mayo Clinic Rochester, MN
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 12, 2005
||December 13, 2011
||United States: Food and Drug Administration
Keywords provided by Mayo Clinic:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 18, 2014
Esophageal Motility Disorders
Digestive System Diseases
Proton Pump Inhibitors
Molecular Mechanisms of Pharmacological Action